Form 4: Puma Biotechnology CEO Alan Auerbach Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
Puma Biotechnology's CEO, Alan Auerbach, sold 33,841 shares of common stock at an average price of $3.1517 per share on January 2, 2025, under a pre-arranged 10b5-1 trading plan.
Summary
- Alan Auerbach, the President and CEO of Puma Biotechnology, sold 33,841 shares of common stock on January 2, 2025.
- The shares were sold at a weighted average price of $3.1517 per share.
- The sale was executed under a pre-existing 10b5-1 trading plan adopted on December 17, 2020.
- The sale was part of a 'sell to cover' program.
- The price range for the sales was between $3.11 and $3.2101 per share.
- Following the transaction, Auerbach beneficially owns 7,029,674 shares of Puma Biotechnology.
Sentiment
Score: 5
Explanation: The document is a routine SEC filing for an insider stock sale under a pre-arranged plan. It doesn't indicate any positive or negative sentiment about the company's performance.
Industry Context
This is a routine filing for insider transactions and is common for executives who have pre-arranged trading plans. It does not necessarily indicate a change in the company's outlook or performance.
Comparison to Industry Standards
- Sales under 10b5-1 plans are a common practice among executives at publicly traded companies, including those in the biotechnology sector.
- These plans allow insiders to sell shares without being accused of trading on non-public information.
- The volume of shares sold is relatively small compared to the total shares owned by the CEO, which is not unusual for these types of transactions.
- Similar transactions can be seen at companies like Amgen (AMGN) and Gilead Sciences (GILD), where executives regularly use 10b5-1 plans for stock sales.
Stakeholder Impact
- The stock sale may have a minor impact on the share price, but it is unlikely to be significant given the relatively small volume and the pre-arranged nature of the transaction.
- The sale does not indicate any change in the company's strategy or outlook.
Key Dates
| Date | Description |
|---|---|
| 12-17-2020 | Adoption date of the 10b5-1(c) sell to cover program. |
| 01/02/2025 | Date of the stock sale transaction. |
| 01/03/2025 | Date of the filing of the SEC Form 4. |
Keywords
Puma Biotechnology, Alan Auerbach, stock sale, 10b5-1 plan, insider trading, PBYI, CEO
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.